Summary
11.26 -0.48(-4.09%)11/06/2024
Amicus Therapeutics Inc (FOLD)
Amicus Therapeutics Inc (FOLD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.09 | 2.05 | 14.84 | 22.52 | 13.34 | 3.67 | 32.04 | -18.75 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 11.26 | |
| Open | 12.53 | |
| High | 12.65 | |
| Low | 10.92 | |
| Volume | 4,374,737 | |
| Change | -0.48 | |
| Change % | -4.09 | |
| Avg Volume (20 Days) | 2,246,431 | |
| Volume/Avg Volume (20 Days) Ratio | 1.95 | |
| 52 Week Range | 9.02 - 14.57 | |
| Price vs 52 Week High | -22.72% | |
| Price vs 52 Week Low | 24.83% | |
| Range | 4.31 | |
| Gap Up/Down | -0.34 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,179 | |
| EBIDTA | -49,200,752 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1800 | |
| WallStreet Target Price | 18.00 | |
| Book Value | 0.4410 | |
| Earnings Per Share | -0.4900 | |
| EPS Estimate Current Quarter | -0.0700 | |
| EPS Estimate Next Quarter | -0.0200 | |
| EPS Estimate Current Year | -0.0600 | |
| EPS Estimate Next Year | 0.3200 | |
| Diluted EPS (TTM) | -0.4900 | |
| Revenues | ||
| Profit Marging | -0.3473 | |
| Operating Marging (TTM) | -0.1963 | |
| Return on asset (TTM) | -0.0508 | |
| Return on equity (TTM) | -1.2610 | |
| Revenue TTM | 423,488,992 | |
| Revenue per share TTM | 1.4210 | |
| Quarterly Revenue Growth (YOY) | 0.2800 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 290,634,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 72.9927 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 19.6954 | |
| Revenue Enterprise Value | 8.2972 | |
| EBITDA Enterprise Value | -35.9859 | |
| Shares | ||
| Shares Outstanding | 296,199,008 | |
| Shares Float | 223,629,976 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.10 | |
| Insider (%) | 0.72 | |
| Institutions (%) | 109.38 | |
11/06 12:54 EST - seekingalpha.com
Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast.
11/06 09:25 EST - zacks.com
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.
11/04 10:55 EST - zacks.com
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
11/01 07:00 EST - globenewswire.com
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
10/30 11:06 EST - zacks.com
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10/28 07:00 EST - globenewswire.com
Amicus Therapeutics to Announce Third Quarter 2024Â Financial Results on November 6, 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024.
Amicus Therapeutics to Announce Third Quarter 2024Â Financial Results on November 6, 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024.
10/24 11:16 EST - zacks.com
Best Momentum Stocks to Buy for October 24th
FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.
Best Momentum Stocks to Buy for October 24th
FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.
10/24 10:11 EST - zacks.com
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
10/24 08:31 EST - zacks.com
New Strong Buy Stocks for October 24th
CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.
New Strong Buy Stocks for October 24th
CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.
10/21 16:18 EST - globenewswire.com
American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas
WASHINGTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- American Citizens Abroad (ACA) has joined parties opposing actions which would narrow the ability of U.S. citizens living overseas to vote. In Pennsylvania, steps have been taken by state officials to make it easier for voters overseas to vote. Plaintiffs in the lawsuit would narrow voter registration rules as they apply to U.S. citizens living overseas.
American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas
WASHINGTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- American Citizens Abroad (ACA) has joined parties opposing actions which would narrow the ability of U.S. citizens living overseas to vote. In Pennsylvania, steps have been taken by state officials to make it easier for voters overseas to vote. Plaintiffs in the lawsuit would narrow voter registration rules as they apply to U.S. citizens living overseas.
10/21 16:17 EST - seekingalpha.com
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.
10/21 10:55 EST - zacks.com
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
10/18 15:47 EST - seekingalpha.com
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%.
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%.
10/18 13:21 EST - zacks.com
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
10/18 11:36 EST - zacks.com
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
10/18 10:56 EST - zacks.com
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Amicus Therapeutics, Inc. (FOLD) is looking like an interesting pick, as it just reached a key level of support. FOLD's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Amicus Therapeutics, Inc. (FOLD) is looking like an interesting pick, as it just reached a key level of support. FOLD's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
10/18 10:56 EST - zacks.com
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
The consensus price target hints at a 43.4% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
The consensus price target hints at a 43.4% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
10/18 07:45 EST - zacks.com
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
10/17 11:07 EST - benzinga.com
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
10/17 07:00 EST - globenewswire.com
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037